Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer

BACKGROUND: Inhibitors of Poly (ADP-Ribose) Polymerases (PARP) provide clinical benefit to patients with breast and ovarian cancers, by compromising the DNA repair activity of cancer cells. Although these agents extend progression-free survival in many patients, responses can be short lived with man...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Brien, Shane, Butticello, Michael, Thompson, Christine, Wilson, Boris, Wyce, Anastasia, Mahajan, Vivek, Kruger, Ryan, Mohammad, Helai, Fedoriw, Andy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436459/
https://www.ncbi.nlm.nih.gov/pubmed/37596538
http://dx.doi.org/10.1186/s12885-023-11260-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436459/
https://www.ncbi.nlm.nih.gov/pubmed/37596538
http://dx.doi.org/10.1186/s12885-023-11260-z

Ejemplares similares